Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad

Am J Ophthalmol. 2016 Sep:169:xiv-xvi. doi: 10.1016/j.ajo.2016.06.040. Epub 2016 Jul 30.

Authors

Daniel E Croft¹, Charles C Wykoff², Stephan Michels³, Usha Chakravarthy⁴, Alan F Cruess⁵

Affiliations

¹ Retina Consultants of Houston, Houston, Texas.
² Retina Consultants of Houston, Houston, Texas; Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas. Electronic address: ccwmd@houstonretina.com.
³ Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland.
⁴ Center for Experimental Medicine, The Queen's University of Belfast, Belfast, United Kingdom.
⁵ Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Canada.

PMID: 27485923
DOI: 10.1016/j.ajo.2016.06.040

No abstract available

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / administration & dosage*
Clinical Trials, Phase III as Topic
Diabetic Retinopathy / drug therapy*
Drug and Narcotic Control / legislation & jurisprudence*
Drug-Related Side Effects and Adverse Reactions / prevention & control
European Union
Humans
Legislation, Drug / organization & administration*
Legislation, Drug / standards
Macular Degeneration / drug therapy*
Pharmaceutical Preparations / administration & dosage*
Retinal Vein Occlusion / drug therapy*
United States
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Pharmaceutical Preparations
VEGFA protein, human
Vascular Endothelial Growth Factor A